JBM Healthcare reports strong interim growth, hikes dividend 77%

JBM (Healthcare) Limited announced interim results for the six months ended September 30, 2025, with revenue climbing 7.7% to HK$429.6 million from HK$399.0 million in the prior year. Profit attributable to equity shareholders rose 20.0% to HK$115.0 million, compared to HK$95.9 million in the corresponding period of 2024. This growth was largely driven by strong performance in branded medicines and proprietary Chinese medicines segments.

The Board declared an interim dividend of HKD 0.0975 per ordinary share for the six months ended September 30, 2025, totaling HK$80.1 million. This marks a 77.3% increase from HKD 0.055 per share in the corresponding 2024 period. The dividend is payable on December 17, 2025.

Key acquisitions during the period included 90% equity in Tin Hee Tong Medicine Factory, Limited for HK$171 million, and 100% equity in Kenford Medical Group Company Limited for HK$38 million. Additionally, the Group acquired further equity interests in Li Chung Shing Tong (Holdings) Limited and Quinwood Limited for an aggregate consideration of HK$84.016 million, increasing its ownership to 71.9% and 92.0% respectively.